Therapy News and Research

RSS

Englerin A possesses high toxicity for kidney cancer cells, researchers discover

Englerin A, a natural product recently discovered in an African plant, possesses high toxicity for kidney cancer cells but low toxicity for other cells. Therefore this compound is potentially qualified for further evaluation toward an application in cancer therapy.

16 Dec 2009

Discovery may yield new treatments for hormone-resistant prostate cancer

Patients with advanced prostate cancer are often treated with hormones, but when the tumours start growing again they have more and different blood vessels, reveals a thesis from the Sahlgrenska Academy, at the University of Gothenburg, Sweden. This discovery paves the way for new treatments for hormone-resistant prostate cancer.

16 Dec 2009

Italian patent issued for NPM1 to test patients with AML

Xenomics, Inc., a developer of transrenal molecular diagnostics, announced today that a key Italian patent covering a unique diagnostic application with critical significance for patients with acute myeloid leukemia (AML) has issued.

16 Dec 2009

Nutrition education may help diabetes patients to adopt better dietary habits

Nine weeks of education about the glycemic index in foods is enough to encourage adults with type 2 diabetes to adopt better dietary habits that result in improvements to their health, recent research suggests.

16 Dec 2009

Low plasma CETP activity associated with increased risk of heart disease, says study

Although seen as a potential heart disease therapy, raising high-density lipoprotein (HDL) cholesterol levels by inhibiting activity of a transfer protein may not be effective, a new study suggests.

16 Dec 2009

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

Genomic Health, Inc. today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer.

16 Dec 2009

DSMB approves advancement of PLX-PAD to intermediate dose level in Phase I clinical trial for CLI treatment

Pluristem Therapeutics Inc. today announced that the independent DSMB approved the advancement to the intermediate dose level of the company’s placenta derived cell therapy, PLX-PAD, in the Phase I clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end stage of peripheral artery disease (PAD).

15 Dec 2009

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) vaccine company, will collaborate with the Gynecologic Oncology Group (GOG), a collaborative research group of the National Cancer Institute (NCI), in a multicenter, Phase II clinical trial of the Company’s lead drug candidate, ADXS11-001 in the treatment of advanced cervix cancer in women who have failed prior cytotoxic therapy.

15 Dec 2009

Positive results from study comparing exenatide once weekly to BYETTA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with type 2 diabetes.

15 Dec 2009

Spinal Restoration receives FDA SPA concurrence letter for its Phase 3 Biostat System study

Spinal Restoration, Inc. announced today it has received a Special Protocol Assessment concurrence letter from the U.S. Food and Drug Administration (FDA) for the design of its Phase 3 study of the Biostat System for the treatment of chronic discogenic low back pain.

15 Dec 2009

Tibotec Virco Virology BVBA acquires Ground Zero Software's LAB TRACKER HIV EMR system

Tibotec Virco Virology BVBA today announced the acquisition of LAB TRACKER(TM) HIV, a customized electronic medical record (EMR) system, from the company Ground Zero Software. LAB TRACKER(TM) HIV is a full-service, scalable software platform designed to meet the complex disease-management needs of health care providers who are treating people living with HIV/AIDS.

15 Dec 2009

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Celgene Corporation announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo.

15 Dec 2009

Interpersonal Psychotherapy may hold hope for teenager girls at risk of obesity

A team of scientists at the Uniformed Services University of the Health Sciences and the National Institutes of Health have piloted psychotherapy treatment to prevent excessive weight gain in teenager girls deemed 'at risk' for obesity.

15 Dec 2009

Preventing tumours from making new blood vessels can also prevent spread of cancer

15 Dec 2009

Pure populations of immature cells that enable male reproduction isolated and transplanted

Reproductive researchers from the University of Pennsylvania and The Children's Hospital of Philadelphia have succeeded in isolating and transplanting pure populations of the immature cells that enable male reproduction in two species-human spermatogonia and mouse gonocytes. These germline stem cells, taken from testis biopsies, demonstrated viability following transplantation to mouse testes within a controlled laboratory setting.

15 Dec 2009

Risks and benefits of CT scans

Doses of radiation from commonly performed computed tomography (CT) scans vary widely, appear higher than generally believed and may contribute to an estimated tens of thousands of future cancer cases, according to two reports in the December 14/28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Dec 2009

Cancer patients with dementia have lower survival rate than patients with cancer alone, says study

A new study published by researchers from the University of Georgia and the Moffitt Cancer Center in Tampa, Fla., has found that cancer patients with dementia have a dramatically lower survival rate than patients with cancer alone, even after controlling for factors such as age, tumor type and tumor stage.

15 Dec 2009

Springer and BMES to publish 'Cardiovascular Engineering and Technology' journal

Springer and the Biomedical Engineering Society (BMES) have founded a new journal Cardiovascular Engineering and Technology (CVET). CVET is a forum for research on all aspects of cardiovascular physiology and medical treatment.

15 Dec 2009

Findings suggest variations in accelerated aging disorders

UT Southwestern Medical Center researchers have provided the most extensive account to date of the unique observable characteristics seen in patients with an extremely rare premature aging syndrome.

15 Dec 2009

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today that it has completed, two months ahead of schedule, enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a unique stem cell therapy for heart failure.

15 Dec 2009

Therapy News and Research

Englerin A possesses high toxicity for kidney cancer cells, researchers discover

Discovery may yield new treatments for hormone-resistant prostate cancer

Italian patent issued for NPM1 to test patients with AML

Nutrition education may help diabetes patients to adopt better dietary habits

Low plasma CETP activity associated with increased risk of heart disease, says study

Results from five new studies on Genomic Health's Oncotype DX breast cancer test announced

DSMB approves advancement of PLX-PAD to intermediate dose level in Phase I clinical trial for CLI treatment

Advaxis to collaborate with GOG in Phase II clinical trial of ADXS11-001

Positive results from study comparing exenatide once weekly to BYETTA

Spinal Restoration receives FDA SPA concurrence letter for its Phase 3 Biostat System study

Tibotec Virco Virology BVBA acquires Ground Zero Software's LAB TRACKER HIV EMR system

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Interpersonal Psychotherapy may hold hope for teenager girls at risk of obesity

Preventing tumours from making new blood vessels can also prevent spread of cancer

Pure populations of immature cells that enable male reproduction isolated and transplanted

Risks and benefits of CT scans

Cancer patients with dementia have lower survival rate than patients with cancer alone, says study

Springer and BMES to publish 'Cardiovascular Engineering and Technology' journal

Findings suggest variations in accelerated aging disorders

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News